drugset
drugset / Trial / NCT06380881

PK/PD Study of SHR-2017 Injection in Patients With Bone Metastases

NCT06380881 ↗

Phase 1 Completed 25 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the pharmacokinetic characteristics, pharmacodynamic characteristics, safety, tolerability and immunogenicity of SHR-2017 injection in patients with bone metastases, and to evaluate the efficacy of SHR-2017 injection in the treatment of skeletal-related event and cancer pain.

Timeline

Start
2024-05-20
Primary completion
2025-08-06
Completion
2025-08-06

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-2017 Unknown — —

Indications

No indication recorded.